This Year's Highlights

• Company launched in April, 2006.
• Medloom patent filed in July, 2006.
• Medloom prototype unveiled in August, 2006 in Denver, Colorado at BIOWest, 2006.

Anticipated Highlights

• Beta testing at US-based medical center to begin in fall, 2006.
• Beta testing at UK-based medical center to begin in spring, 2007.
• Medloom Commercial version 1.0 subscribed to by first customer in late 2007.

Corporate Mission

Lead Horse Technologies, Inc. (?LHT? or the ?Company?) is a start-up bioinformatics company founded on the simple premise that the integration of patient medical records with information derived from clinical trials, post-marketing surveillance registries and databases, pharmaceutical package inserts, and other sources will empower healthcare professionals (HCPs) to make medical treatment decisions that are safer and more effective, resulting in lowered healthcare costs to the subscriber. The Company is developing a biomedical informatics-based product (?Medloom?) that will change the standard of healthcare and become indispensable to pharmaceutical companies and insurance organizations in terms of increasing the benefit/risk ratios of each drug in the database, improving drug response rates, and lowering the rates of adverse drug events, the latter issue accounting for nearly $200 billion per year in the US. Tying the use of Medloom to the costs of adverse events identified and potentially prevented provides a quantifiable value to each enterprise-scale customer and fills an unmet medical need that is sought by subscribing organizations and doctors alike. LHT is being co-launched from locations in Denver, Colorado to capitalize on the domestic and North American markets, and Northern Ireland to take advantage of the expertise in AI and bioinformatics programming indigenous to that area and from which to pursue opportunities throughout Europe. The flagship product is planned for prescribers of drugs for the treatment of rheumatoid arthritis, cardiovascular disease, and diabetes, with product line expansion to focus on many other immune-mediated inflammatory disorders. The prototype system integrates patient-specific data from electronic medical records and other sources with pharmaceutical product information to deliver individualized medical treatment support to the HCP, whether in the office or from remote locations.